Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · IEX Real-Time Price · USD
200.16
-10.60 (-5.03%)
Sep 30, 2022 4:00 PM EDT - Market closed
-5.03%
Market Cap 24.02B
Revenue (ttm) 884.25M
Net Income (ttm) -980.72M
Shares Out 120.03M
EPS (ttm) -7.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,684,601
Open 208.16
Previous Close 210.76
Day's Range 199.11 - 216.89
52-Week Range 117.58 - 236.80
Beta 0.57
Analysts Buy
Price Target 243.50 (+21.7%)
Earnings Date Oct 26, 2022

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; G... [Read more...]

Industry Biotechnology
IPO Date May 28, 2004
CEO John Maraganore
Employees 1,665
Stock Exchange NASDAQ
Ticker Symbol ALNY
Full Company Profile

Financial Performance

In 2021, ALNY's revenue was $844.29 million, an increase of 71.31% compared to the previous year's $492.85 million. Losses were -$852.82 million, -0.64% less than in 2020.

Financial Statements

Analyst Forecast

According to 31 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is 243.5, which is an increase of 21.65% from the latest price.

Price Target
$243.5
(21.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis wi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from exploratory endpoints and additional analyses of pres...

2 days ago - Business Wire

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

1 week ago - Zacks Investment Research

Alnylam Announces New Management Appointments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of two new members to the management team – Piyush...

1 week ago - Business Wire

Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorizat...

1 week ago - Business Wire

Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtable” w...

1 week ago - Business Wire

Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunt...

Target knockdown and safety results support continued clinical development Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical c...

Other symbols: REGN
2 weeks ago - PRNewsWire

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunt...

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the cli...

Other symbols: REGN
2 weeks ago - Business Wire

Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis wit...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Ph...

2 weeks ago - Business Wire

Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offeri...

2 weeks ago - Business Wire

Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 milli...

2 weeks ago - Business Wire

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 weeks ago - Zacks Investment Research

Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the APOLLO-B Phase 3 study of patisiran, an ...

3 weeks ago - Business Wire

Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stan...

3 weeks ago - Business Wire

Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market

They're both soaring thanks to a handful of recent catalysts.

Other symbols: SWAV
4 weeks ago - The Motley Fool

Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Dise...

BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam® Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau's [F-18]MK-6240, ...

1 month ago - Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others

Biotech stocks are scorching right now. But the best of the best have strong gains.

Other symbols: AXSMBLUEKRTX
1 month ago - Investors Business Daily

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 ...

1 month ago - Business Wire

Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.

1 month ago - Zacks Investment Research

Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Dire...

1 month ago - Business Wire

Is Alnylam Stock Poised For More Gains After A Stellar 50% Rise In A Month?

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

1 month ago - Forbes

3 Biopharmas on Buyout Watch

These three biotech companies could be headed for a buyout soon.

Other symbols: AXSMKRTX
1 month ago - The Motley Fool

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyo...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study...

1 month ago - Business Wire

Is This Unknown Growth Stock a Buy After Its Blast Off?

It's pursuing a smart and tightly focused drug development strategy that could pay off big.

1 month ago - The Motley Fool

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction. The post Alnylam's Hot Streak Cools As Expert Questions Uptake F...

1 month ago - Investors Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editin...

Other symbols: NTLA
1 month ago - Investors Business Daily